ProLynx technology overcomes major limitations of conjugates currently used for half-life extension and allows you to sustain desired levels of drugs for predictable periods.
The ProLynx β-eliminative drug delivery system uses sets of novel linkers that are pre-programmed to cleave at different rates to allow the controlled, predictable and sustained release of native, active drugs—peptides, proteins and small molecules—from circulating and semi-solid macromolecular conjugates for weeks to months.
We have multiple pre-clinical and clinical candidates available for licensing.
At ProLynx, we know that science thrives on collaboration. We are always seeking new partnerships with pharmaceutical companies to design and prepare drug conjugates for half-life extension.
This cover art illustration depicts microspheres formed from highlyhomogeneous Tetra-PEG hydrogels that serve as sub-cutaneous depots for a novel drug-delivery system. Drugs – peptides, proteins or small molecules – are covalently attached to the hydrogel backbone by self-cleaving β-eliminative linkers that are tuned to release the drug at a specified rate. Slower self-cleaving β-eliminative linkers are also incorporated in the cross-links of the hydrogel to trigger biodegradation of the microspheres after the drug has been released.